很多作为抗癌治疗手段可获得的体内放射制剂经由肾脏过滤并通过尿液排出。此文中，放射医学、核医学/分子影像学和放射诊疗计划的医师领导者以及辐射安全官员协同合作，制定了治疗性放射制剂在术前或治疗当日尿失禁患者中的给药决策指南。我们讨论了根据尿失禁程度对患者进行筛查和尿液采集策略以及随后协调医疗护理的挑战和机遇。鲁特铒-177（177Lu）基于放射制剂治疗的临床案例展示了我们所操作的程序。我们所关注的尿失禁的主要管理问题为皮肤放射损伤、红肿、感染或疼痛。为此，我们制定了有关识别和处理与尿失禁相关的不良事件的临床实践指南。本研究中注意到了尿失禁的常见不良事件。我们的治疗性放射制剂安全给药的操作指南值得进一步研究，并应在所有放射制剂治疗剂上持续评估。版权所有 ©2023年 Health Physics Society.

Many parenteral radiopharmaceuticals available as anticancer therapy are filtered by the kidneys and excreted in the urine. Here, physician leaders of radiation medicine, nuclear medicine/molecular imaging, and the radiotheranostics programs as well as radiation safety officers, collaborated to develop a decision-making guideline for the administration of therapeutic radiopharmaceuticals in patients with pretherapy or day-of-treatment incontinence. We discussed challenges and opportunities in the screening of patients in urine collection strategies according to grade of urinary incontinence and in subsequent coordination of care. Lutetium-177 (177Lu)-based radiopharmaceutical therapies provided clinical examples of how our procedures were operationalized. Our key management issues of urinary incontinence were cutaneous radiation injury and redness, infection, or pain. In response, we developed clinical practice guidelines for the recognition and management of incontinence-related adverse events. Common adverse events of urinary incontinence were noted in this study. Our how-to guideline for the safe administration of therapeutic radiopharmaceuticals for patients with urinary incontinence warrants further investigation and should continue to be evaluated across all radiopharmaceutical therapy agents.Copyright © 2023 Health Physics Society.